Hello, Guest!

Welcome to MS Money Moves!

Empowering a generation & individuals through comprehensive, objective & digestible research in Biotech. Investing in biotech presents immense opportunity. Enter the right stock at the right time and you can see 10x+ returns! The MS team is uniquely positioned to empower you with the research you need to capture those gains.

Don’t miss out on
our next 100%+ pick!

How It Works

MS gives you an edge over other investors through our comprehensive insights in biotech stocks delivered via SMS, Email & our website.
The days of needing a Ph.D & taking weeks to research investments is over! 
Sign up for a Monthly or Quarterly subscription
Begin receiving our SMS alerts & daily trade insights sent to your inbox each night
Login to your account to read our in depth research on our favorite stocks we are personally buying
Lock in profits and repeat!


The MS executive team, although young, has extensive experience between them and complimentary skill sets gained through actively investing in the biotech industry. Over the years they have developed a strategy and fine-tuned research methods, yielding returns that have proven to outpace the market and many analysts. 

Zion Miller

CEO & Co Founder

Sultan Beardsley

COO & Co Founder

Chris Stang


Michael Lipari


Travis Kellerman




February 19, 2020 by Sultan Beardsley
PT= Price target (i.e our approximate exit price)Unless stated otherwise, the price next to the ticker is a suitable entry price. Let us know if you are not receiving SMS text alerts (info@msmoneymoves.com) Let us know if you have any comments or feedback regarding the format of Trade Insights.
Dario Health (Nasdaq: DRIO) is Poised For a Transformative Year in 2020
January 31, 2020 by Sultan Beardsley
Investment Thesis: This year I had the opportunity of attending the 38th Annual JP Morgan Healthcare Conference in San Francisco, CA. Amid the hustle and bustle of pharma execs and investors, I caught wind of an emerging trend in 2020, Digital Therapeutics (DTx).
Epizyme’s Tazemetostat: The Background
February 16, 2020 by Chris Stang
Epizyme (EPZM) is a peculiar mid-cap biotechnology company with a pipeline in a candidate. That candidate is tazemetostat (marketed as Tazverik). Tazemetostat is an oral small molecule inhibitor of the methyltransferase, EZH2, and some EZH2 gain-of-function mutations including the Y646X and A687V mutations.


MS Money Move and its Chief Operating Officer who is a scientist and individual investor, as well as its affiliates are not registered financial advisors. Our posts should serve as educational material to help you conduct due diligence research. Posts and articles are not directives or recommendations to invest in any security. We reserve the right to buy or sell any security for ourselves without any notification except when required by law. We are not responsible for the action of our affiliates. Investment theses may change due to the variable nature of the securities market. Because of this there is great risk when investing in stocks and options which can result is capital loss. Additionally, past performance by MS Money Moves or any security is not a predictor of future performance. Everyone should conduct their own research and due diligence before making an investment decision. We recommend you consult a financial advisor regarding any investment action.

The biotech sector is especially volatile. Stock prices may fluctuate substantially based on material or nonmaterial developments. We encourage everyone to familiarize themselves with clinical trial processes, relevant terminology, FDA/SEC rules and regulations, and the general processes of drug & therapy development/approval. Always do independent research in a security prior to investing.